5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
United Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 37.43%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for United Therapeutics's 5-Year ROIIC % or its related term are showing as below:
UTHR's 5-Year ROIIC % is ranked better than 84.76% of 899
companies
in the Drug Manufacturers industry
Industry Median: 2.41
vs UTHR: 37.43
United Therapeutics (NAS:UTHR) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
United Therapeutics 5-Year ROIIC % Related Terms
United Therapeutics 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for United Therapeutics's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UTHR vs VTRS, NBIX, ZTS: 5-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics 5-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's 5-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
United Therapeutics (UTHR) has a 5-Year ROIIC % of 37.43 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on United Therapeutics and its competitors. According to the industry distribution chart, United Therapeutics ranks #137 out of 899 companies in the Drug Manufacturers industry, placing it in the top 15.2%.
Is United Therapeutics' 5-Year ROIIC % too high?
United Therapeutics' current 5-Year ROIIC % is 37.43. The Drug Manufacturers industry median 5-Year ROIIC % is 2.41. United Therapeutics' value of 37.43 is 1453.1% above this industry median. Based on the distribution chart, United Therapeutics ranks #137 out of 899 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' 5-Year ROIIC % compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #137 out of 899 companies for 5-Year ROIIC %. This places United Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median 5-Year ROIIC % is 2.41. United Therapeutics' value of 37.43 is 1453.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Drug Manufacturers company?
The median 5-Year ROIIC % among Drug Manufacturers companies is 2.41, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current 5-Year ROIIC % of 37.43 is 1453.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median 5-Year ROIIC % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current 5-Year ROIIC % is 37.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.86, compared to a current price of $563.70 — trading 45.7% above its estimated fair value. The current 5-Year ROIIC % is 37.43 and 1453.1% above the Drug Manufacturers industry median of 2.41. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For United Therapeutics (UTHR), the current 5-Year ROIIC % is 37.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (UTHR) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of $563.70 is trading 45.7% above its estimated GF Value™ of $386.86.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for UTHR:
5-Year ROIIC %: 37.43
GF Value™: $386.86 vs. price of $563.70 (45.7% above fair value)
Industry Position: 1453.1% above the Drug Manufacturers median (#137 of 899)
No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score
Get the complete analysis for UTHR
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTHR has been successfully added to your 
